Efficacy and safety of CBDCA/ETP/ICI combination therapy for extensive-stage small cell lung cancer in elderly patients

被引：0
|
作者：
Fukasawa, Naoto [1 ]
Nakamura, Yukiko [1 ]
Miyazaki, Kazuhito [1 ]
Ikeda, Toshiki [1 ]
Higashi, Yuko [1 ]
Aga, Masaharu [1 ]
Hamakawa, Yusuke [1 ]
Taniguchi, Yuri [1 ]
Misumi, Yuki [1 ]
Agemi, Yoko [1 ]
Shimokawa, Tsuneo [1 ]
Okamoto, Hiroaki [1 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Resp Med, Yokohama, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P50-5
引用
收藏
页码：S1460 / S1460
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [32] Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
    Wang, Bi-Cheng
    Xiao, Bo-Ya
    Li, Peng-Cheng
    Kuang, Bo-Hua
    Chen, Wang-Bing
    Li, Pin-Dong
    Lin, Guo-He
    Liu, Quentin
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [33] Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
    Qing Chen
    Yan Li
    Wenjie Zhang
    Chen Wang
    Shengjie Yang
    Qisen Guo
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 401 - 408
  • [34] Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status
    Agarwal, Muskan
    Liu, Alex
    Almquist, Daniel
    Langlais, Blake T.
    Leventakos, Konstantinos
    Yu, Nathan Y.
    Manochakian, Rami
    Ernani, Vinicius
    CANCER, 2023, 129 (22) : 3546 - 3553
  • [35] Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer
    Ying, Xixi
    Shi, Zheng
    Shao, Rongjun
    You, Guangxian
    Song, Zhengbo
    NEOPLASMA, 2024, 71 (03) : 297 - 305
  • [36] Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer
    Johnson, BE
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) : 254 - 255
  • [37] Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
    Chen, Qing
    Li, Yan
    Zhang, Wenjie
    Wang, Chen
    Yang, Shengjie
    Guo, Qisen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (02) : 401 - 408
  • [38] Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
    Patrice, Grace I.
    Lester-Coll, Nataniel H.
    Yu, James B.
    Amdahl, Jordan
    Delea, Thomas E.
    Patrice, Stephen J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (01): : 97 - 106
  • [39] Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis
    Tang, Jiayi
    Wang, Tianlei
    Wu, Hongwei
    Bao, Xinrui
    Xu, Ke
    Ren, Tao
    BMC CANCER, 2024, 24 (01)
  • [40] Progress in the diagnosis and treatment of extensive-stage small cell lung cancer
    Fei Xu
    Xiaoli Ren
    Yuan Chen
    Qianxia Li
    Ruichao Li
    Yu Chen
    Shu Xia
    OncologyandTranslationalMedicine, 2019, 5 (01) : 33 - 42
12345